PENICILLIN V POTASSIUM
Clinical safety rating: safe
Human studies have proved safety
Penicillin V is a bactericidal antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting transpeptidation and activating autolytic enzymes.
| Metabolism | Primarily excreted unchanged by the kidneys; minor hepatic metabolism to penicilloic acid. |
| Excretion | Renal excretion of unchanged drug accounts for 20-40% of the dose via glomerular filtration and tubular secretion; biliary excretion is minor (<1%). Fecal elimination is negligible. |
| Half-life | 0.5-1 hour in patients with normal renal function; prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min). Clinical context: requires frequent dosing due to short half-life. |
| Protein binding | 60-80% bound to serum albumin; binding is saturable at high concentrations. |
| Volume of Distribution | 0.3-0.5 L/kg; approximates extracellular fluid volume; limited penetration into CSF unless meninges inflamed. |
| Bioavailability | Oral: 60-70% (variable, decreased by food); absorption is reduced in achlorhydria. |
| Onset of Action | Oral: 30-60 minutes for detectable serum concentrations; clinical effect for susceptible infections typically within 24-48 hours. |
| Duration of Action | 4-6 hours after oral administration; provides sustained levels above MIC for susceptible organisms for 4-6 hours. Clinical notes: requires dosing every 6-8 hours. |
250-500 mg orally every 6-8 hours.
| Dosage form | FOR SOLUTION |
| Renal impairment | CrCl 10-50 mL/min: 250-500 mg every 8-12 hours; CrCl <10 mL/min: 250-500 mg every 12-18 hours. |
| Liver impairment | No dosage adjustment required for Child-Pugh Class A, B, or C. |
| Pediatric use | Children >12 years: 250-500 mg orally every 6-8 hours; Children 1-12 years: 25-50 mg/kg/day orally divided every 6-8 hours; Infants <1 year: 25-50 mg/kg/day orally divided every 6-8 hours. |
| Geriatric use | No specific dose adjustment; consider renal function and monitor for adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Probenecid may decrease excretion Serious and occasionally fatal hypersensitivity reactions have been reported.
| Breastfeeding | Penicillin V potassium is excreted into breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.2. It is considered compatible with breastfeeding, as it is unlikely to cause adverse effects in the nursing infant. However, theoretical risks include alteration of infant gut flora and allergic sensitization. Monitoring for diarrhea or rash in the infant is advisable. |
| Teratogenic Risk | Penicillin V potassium is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, and there are no adequate and well-controlled studies in pregnant women. It is generally considered safe throughout all trimesters, as penicillins are not associated with teratogenic effects. No increased risk of congenital malformations has been observed with first-trimester exposure. |
■ FDA Black Box Warning
No FDA black box warnings.
| Common Effects | Diarrhea |
| Serious Effects |
Hypersensitivity to penicillins; infectious mononucleosis (relative contraindication due to risk of maculopapular rash).
| Precautions | Serious hypersensitivity reactions including anaphylaxis; use with caution in renal impairment; avoid in patients with mononucleosis due to high risk of rash; prolonged use may lead to superinfection; Clostridium difficile-associated diarrhea possible. |
Loading safety data…
| Fetal Monitoring | No specific monitoring is required beyond standard prenatal care. However, for prolonged therapy or high doses, monitor for maternal gastrointestinal effects (e.g., diarrhea) and signs of superinfection. Fetal monitoring is not routinely indicated unless the mother has a severe infection or is receiving high doses near term. |
| Fertility Effects | There is no evidence that penicillin V potassium adversely affects fertility in humans. Animal studies have not reported impairment of fertility. No reproductive toxicity has been observed. |